Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00178971
Status:
COMPLETED
Last Update Posted:
2017-06-07
First Post:
2005-09-12
Brief Title:
Serotonin 1A Agonists and Cognition in Schizophrenia
Sponsor:
Northwestern University
Organization:
Northwestern University
Study Overview
Official Title:
Serotonin 1A Agonists and Cognition in Schizophrenia
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications Patients will be assigned to take active medication Busparor placebo along with their prescribed antipsychotic medication for six weeks Patients memory and problem-solving ability will be tested before and after medication
Detailed Description:
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with olanzapine or risperidone for at least three months randomized to receive adjunctive treatment with a 5-HT1A agonist buspirone 15-30 mgdayor placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None